Mankind Pharma Share Price
₹2,871.75 -44.9 (-1.54%)
28 Dec, 2024 02:13
Start SIP in MANKIND
Start SIPPerformance
- Low
- ₹2,865
- High
- ₹2,944
- 52 Week Low
- ₹1,901
- 52 Week High
- ₹3,055
- Open Price₹2,925
- Previous Close₹2,917
- Volume246,296
Investment Returns
- Over 1 Month + 11.28%
- Over 3 Month + 6.95%
- Over 6 Month + 34.23%
- Over 1 Year + 49.12%
Smart Investing Starts Here Start SIP with Mankind Pharma for Steady Growth!
Mankind Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 56
- PEG Ratio
- 1.6
- Market Cap Cr
- 118,479
- P/B Ratio
- 12.4
- Average True Range
- 110.42
- EPS
- 51.26
- Dividend Yield
- 0
- MACD Signal
- 55.82
- RSI
- 59.94
- MFI
- 77.24
Mankind Pharma Financials
Mankind Pharma Technicals
EMA & SMA
Current Price
₹2,871.75
-44.9
(-1.54%)
- Bullish Moving Average 14
- Bearish Moving Average 2
- 20 Day
- ₹2,758.55
- 50 Day
- ₹2,663.88
- 100 Day
- ₹2,556.02
- 200 Day
- ₹2,389.93
Resistance and Support
2893.6
- R3 3,000.95
- R2 2,972.45
- R1 2,922.10
- S1 2,843.25
- S2 2,814.75
- S3 2,764.40
Mankind Pharma Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2024-11-05 | Quarterly Results | |
2024-07-31 | Quarterly Results | |
2024-05-15 | Audited Results & Others | To evaluate various options or proposals for raising funds through any of the permissible modes, subject to the receipt of necessary approvals. |
2024-01-31 | Quarterly Results | |
2023-10-31 | Quarterly Results |
Mankind Pharma F&O
About Mankind Pharma
- NSE Symbol
- MANKIND
- BSE Symbol
- 543904
- ISIN
- INE634S01028
Similar Stocks to Mankind Pharma
Mankind Pharma FAQs
Mankind Pharma share price is ₹2,871 As on 28 December, 2024 | 01:59
The Market Cap of Mankind Pharma is ₹118478.9 Cr As on 28 December, 2024 | 01:59
The P/E ratio of Mankind Pharma is 56 As on 28 December, 2024 | 01:59
The PB ratio of Mankind Pharma is 12.4 As on 28 December, 2024 | 01:59
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.